1 Citation (Scopus)


Background: Genetic factors, dysregulation in the endocrine system, cytokine and paracrine factors are implicated in the pathogenesis of familial short stature (FSS). Nowadays, the treatment choice for FSS is limited, with only recombinant human growth hormone (rhGH) being available. Methods: Herein, starting from the identification of 122 genetic loci related to FSS, we adopted a genetic-driven drug discovery bioinformatics pipeline based on functional annotation to prioritize crucial biological FSS-related genes. These genes were suggested to be potential targets for therapeutics. Results: We discovered five druggable subnetworks, which contained seven FSS-related genes and 17 druggable targerts. Conclusions: This study provides a valuable drug repositioning accompanied by corresponding targetable gene clusters for FSS therapy.

Original languageEnglish
Article number91
JournalJournal of Biomedical Science
Issue number1
Publication statusPublished - Nov 7 2019


  • Drug repositioning/repurposing
  • Familial short stature
  • Genome-wide association study
  • Pharmacogenomics
  • Single-nucleotide polymorphism

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)


Dive into the research topics of 'Genomic interrogation of familial short stature contributes to the discovery of the pathophysiological mechanisms and pharmaceutical drug repositioning'. Together they form a unique fingerprint.

Cite this